reason report
hard get excit given competit headwind valuat
bottom line updat model follow result
updat tax ep guidanc overal model chang
rel minor lower elanco outlook
bit conserv lower anim health
revenu account management comment flat slightli
y/i growth also updat tax rate
forecast ep compar management ep
guidanc rang surpris event
call pressur stock today lesser extent
broader larg cap pharma stock comment
earlier note link view today move overreact
investor pose legitim risk diabet anim
health franchis highlight earlier note dcf-base
pt modestli increas due benefit
like quarter new product volum grew
offset volum loss recent ciali
strong quarter grow trulic
new-to-brand share space overal space
grow y/i critic year trulic key data
come cardiovascular outcom studi rewind competitor
nvo mp alreadi shown benefit once-daili agonist
victoza earli launch dynam ozemp novo qw
agonist show superior glucos lower weight loss
trulic studi includ cv result clinic
data portion label close watch data nvo oral
semaglutid also repres sentiment headwind although believ
trulic superior devic once-weekli dose allow cont
like quarter global revenu anim health ex-
fx declin driven primarili volum eros access
headwind competit pressur management comment conf
call cont diabet price pressur also rais concern
long-term growth prospect particularli insulin franchis
howev management also note diabet segment growth driver trulic
jardianc inhibitor diabet well posit price
payer access investor remain concern price
access despit compani state ambit step
game deal found lli move util
newli access cash pay debt bit perplex despit
particular interest ad oncolog portfolio
compani inform leerink partner llc research
revenu includ novarti anim health
exclud intang amort includ novarti anim start
methodolog dcf valuat
net debt total capit
price-to-earnings lt ep growth
estimate lt ep growth compound-annual-growth-rate
pleas refer page import disclosur price chart analyst certif
